Insider Selling: RxSight, Inc. (NASDAQ:RXST) Insider Sells 1,330 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 1,330 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $46.13, for a total transaction of $61,352.90. Following the transaction, the insider now owns 42,246 shares of the company’s stock, valued at approximately $1,948,807.98. This represents a 3.05 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ilya Goldshleger also recently made the following trade(s):

• On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $51.91, for a total value of $161,180.55.
• On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.79, for a total transaction of $154,349.00.
• On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.64, for a total transaction of $156,984.00.
• On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.68, for a total transaction of $154,008.00.
• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total value of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.78, for a total value of $154,318.00.
• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.19, for a total value of $155,589.00.
• On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total value of $155,279.00.
• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total transaction of $149,606.00.
• On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $48.01, for a total transaction of $148,831.00.

RxSight Price Performance

RXST stock opened at $45.05 on Friday. RxSight, Inc. has a 1 year low of $27.07 and a 1 year high of $66.54. The company’s 50-day moving average is $50.32 and its 200-day moving average is $53.27. The stock has a market capitalization of $1.82 billion, a PE ratio of -54.28 and a beta of 1.19.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on RXST. Jefferies Financial Group began coverage on shares of RxSight in a research note on Tuesday, October 29th. They set a “buy” rating and a $72.00 price target for the company. Oppenheimer lowered their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research note on Tuesday, August 6th. Wells Fargo & Company cut their price target on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Stifel Nicolaus dropped their price objective on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 target price on shares of RxSight in a research note on Friday, September 13th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $61.63.

Hedge Funds Weigh In On RxSight

A number of institutional investors have recently modified their holdings of the company. Geode Capital Management LLC raised its holdings in shares of RxSight by 17.7% in the 3rd quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock worth $40,398,000 after acquiring an additional 122,775 shares during the last quarter. Barclays PLC increased its holdings in RxSight by 389.8% during the third quarter. Barclays PLC now owns 58,786 shares of the company’s stock worth $2,906,000 after buying an additional 46,783 shares during the last quarter. MML Investors Services LLC bought a new stake in shares of RxSight in the 3rd quarter worth approximately $452,000. MCIA Inc raised its stake in shares of RxSight by 5.7% in the third quarter. MCIA Inc now owns 8,459 shares of the company’s stock valued at $385,000 after buying an additional 459 shares during the period. Finally, State Street Corp lifted its holdings in RxSight by 8.3% during the third quarter. State Street Corp now owns 817,671 shares of the company’s stock valued at $40,417,000 after purchasing an additional 62,349 shares during the last quarter. 78.78% of the stock is owned by institutional investors and hedge funds.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.